
**Tools for Practice** is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,000 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. <a href="https://www.acfp.ca">www.acfp.ca</a>

March 30, 2015



Corticosteroid shots and knees: A match made in osteoarthritis heaven?

Clinical Question: What is the effectiveness of intraarticular corticosteroid injections in knee osteoarthritis?

Bottom Line: Corticosteroid intra-articular knee injections reduce osteoarthritis pain ~40% more than placebo and one in every 3-5 patients injected will have global symptom improvement in the first four weeks. Long-term pain relief is less certain but serious adverse events, like joint infection, are very rare (one in >14,000).

## **Evidence:**

- We found six systematic reviews,<sup>1-6</sup> each with 5-13 Randomized Controlled Trials (RCTs) and 207-648 patients total. Comparing corticosteroid (triamcinolone 20-40 mg most common, methylprednisolone 40-120 mg next most common) to placebo injections.
  - o Pain: On a 100 point Visual Analogue Scale (VAS) steroids statistically significantly reduced pain (from ~54 baseline)<sup>4</sup> more than placebo:
    - 21-22 points lower at one week,<sup>1,2</sup> 16.5 points lower at two weeks,<sup>3</sup> 7.4 points at 3-4 weeks.<sup>1</sup>
      - Average ~15 points better between 1-4 weeks.<sup>4</sup>
    - At later time points, difference is non-statistically significant.<sup>1</sup>
    - Maximal effect may occur at 1.5 weeks.<sup>4</sup>
  - o Pain: Hitting a particular pain reduction target or global improvement:
    - 74-78% for steroid vs. 45-54% placebo. 1-3
      - Number Needed to Treat (NNT)=3-5, at 1-4 weeks.<sup>1-3</sup>
    - Results at >4 weeks inconsistent: Two found no effect,<sup>1,2</sup> one reports NNT=5 at 16-24 weeks.<sup>3</sup>
  - o Function and stiffness not reliably changed.<sup>5</sup>
  - o Issues: Included RCTs were frequently small (≤50) and often short (example one week). Pooled results also often included few studies and lacked power.<sup>1-6</sup>

## Context:

- Overall, corticosteroid injections may be most efficacious therapies for knee osteoarthritis in the first 1-4 weeks.<sup>4,5</sup>
- Unclear if one type of steroid better than another.<sup>7</sup>

- Maximum frequency ~4/year.
  - o RCT injected steroids 4x/year for two years without any harms.8
  - o Cohort of ≥4 injections/year found no harm.9
- Which clinical features influence success is unclear<sup>10,11</sup> but increased radiographic severity may reduce effectiveness while increased clinical severity (pain and stiffness) may improve effectiveness.<sup>10</sup>
- Risk of joint infection one in 14,000-77,000 following intra-articular injection.
- Guidelines generally recommend corticosteroid intra-articular injections, <sup>13,14</sup> although uncertainty (due to insufficient long-term evidence) remains. <sup>15</sup>

#### Authors:

Jeff Jamieson MD, G Michael Allan MD CCFP

# Disclosure:

Authors do not have any conflicts to disclose.

### References:

- 1. Godwin M, Dawes M. Can Fam Physician. 2004; 50:241-8.
- 2. Bellamy N, Campbell J, Welch V, et al. Cochrane Database Syst Rev. 2006; (2):CD005328.
- 3. Arroll B, Goodyear-Smith F. BMJ. 2004 Apr 10; 328(7444):869.
- 4. Bjordal JM, Klovning A, Ljunggren AE, et al. Eur J Pain. 2007; 11:125-38.
- 5. Bannuru RR, Schmid CH, Kent DM, et al. Ann Intern Med. 2015; 162:46-54.
- 6. Hepper CT, Halvorson JJ, Duncan ST, et al. J Am Acad Orthop Surg. 2009; 17:638-46.
- 7. Garg N, Perry L, Deodhar A. Clin Rheumatol. 2014; 33:1695-706.
- 8. Raynauld JP, Buckland-Wright C, Ward R, et al. Arthritis Rheum. 2003; 48:370-7.
- 9. Balch HW, Gibson JM, El-Ghobarey AF, et al. Rheumatol Rehabil. 1977; 16:137-40.
- 10. Maricar N, Callaghan MJ, Felson DT, et al. Rheumatology (Oxford). 2013; 52:1022-32.
- 11. Hirsch G, Kitas G, Klocke R. Semin Arthritis Rheum. 2013; 42:451-73.
- 12. Jones T, Kelsberg G, Safranek S. Am Fam Physician. 2014; 90:115-6.
- 13. Hochberg MC, Altman RD, April KT, et al. Arthritis Care Res (Hoboken). 2012; 64:465-74.
- 14. Richmond J, Hunter D, Irrgang J, et al. J Am Acad Orthop Surg. 2009; 17:591-600.
- 15. Jevsevar DS, Brown GA, Jones DL, et al. J Bone Joint Surg Am. 2013; 95:1885-6.

**Tools for Practice** is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practicing family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity.

The ACFP has supported the publishing and distribution of the Tools for Practice library since 2009. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at <a href="http://bit.ly/signupfortfp">http://bit.ly/signupfortfp</a>. Archived articles are available at no extra cost on the ACFP website.

You can now earn credits on Tools for Practice! In August 2014, the ACFP launched <u>GoMainpro, an online accreditation tool</u> to help facilitate MAINPRO® accreditation for the ACFP's Tools for Practice library which has been accredited for Mainpro-M1 credits by the College of Family Physicians of Canada (CFPC). The combination of the CFPC's Direct Entry Program and GoMainpro's tracking and reporting features provide an easy and convenient way to earn Mainpro-M1 credits.

This communication	reflects the oninion	of the authors an	d does not necess	sarily mirror the n	erspective and policy
of the Alberta Colleg	ge of Family Physician	ns.	u does not neces:	sarily militor the pr	erspective and policy